Novel oncolytic Sendai viruses (SeV) for the virotherapeutic treatment of HCC
M Zimmermann, S Armeanu-Ebinger, S Bossow, J Lampe, I Smirnow, S Lange, TS Weiss, W Neubert, NP Malek, UM Lauer, M Bitzer · Zeitschrift für Gastroenterologie · 2012 · Heft 01
Bibliografische Angaben
Zusammenfassung
Introduction: So far, most hepatocellular carcinomas (HCC) cannot be cured efficiently. Thus, virotherapy provides a great potential, especially when broad resistances to chemotherapeutic compounds exist. The resistance-breaking mechanism of virotherapeutics is based on selective replication of oncolytic viruses in tumor cells leading to a highly efficient oncolysis. Naturally, murine parainfluenza virus type I (Sendai virus, SeV) is highly efficient in infecting nearly all human cell types; however, infectious progeny viruses are not produced leading to an immediate abrogation of the viral live cycle. Aim: Deve…
